May 13, 2016
May 12, 2016
April 18, 2016
March 28, 2016
CASI Pharmaceuticals CEO Ken K. Ren, PhD rang the closing bell at NASDAQ on Thursday, June 11, 2015 4PM.
CASI is a biopharmaceutical company focused on the acquisition, development, and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market, with a focus on China and the U.S.
CASI's turnaround turns eastward; firm seeks to be Celgene of China
Senescence as a Mechanism of Resistance to Aurora Kinase Inhibition with ENMD-2076 in p53 mutated Triple-Negative Breast Cancer (TNBC) Models
￼A Phase II Study of Oral ENMD-2076 in Advanced Soft Tissue Sarcomas